Table 1 Clinical characteristics and radiomics score of patients
Training cohort (n = 101) | Validation cohort (n = 50) | |||||
|---|---|---|---|---|---|---|
Without CEI (n = 62) | With CEI (n = 39) | p value | Without CEI (n = 24) | With CEI (n = 26) | p value | |
Gender | ||||||
Female | 4 (6.5%) | 2 (5.1%) | 1 | 1 (4.2%) | 1 (3.8%) | 1 |
Male | 58(93.5%) | 37 (94.9%) | 23 (95.8%) | 25 (96.2%) | ||
Age (years) | 61 (56, 65) | 58 (55, 62) | 0.056 | 61 (56, 66) | 61 (53, 67) | 0.899 |
Primary site | 0.012 | 0.201 | ||||
Pyriform sinus | 38 (61.3%) | 12 (30.8%) | 13 (54.2%) | 8 (30.8%) | ||
Posterior pharyngeal wall | 15 (24.2%) | 17 (43.6%) | 6 (25.0%) | 12 (46.2%) | ||
Postcricoid region | 9 (14.5%) | 10 (25.6%) | 5 (20.8%) | 6 (23.1%) | ||
Maximum diameter (mm) | 33 (28, 39) | 38 (23, 44) | 0.001 | 30 (24, 36) | 41 (36, 48) | < 0.001 |
Clinical T stage | 0.001 | 0.005 | ||||
T1-2 | 23 (37.1%) | 3 (7.7%) | 12 (50.0%) | 3 (11.5%) | ||
T3-4 | 39 (62.9%) | 36 (92.3%) | 12 (50.0%) | 23 (88.5%) | ||
Clinical N stage | 0.830 | 0.164 | ||||
N0 | 16 (25.8%) | 10 (25.6%) | 7 (29.2%) | 3 (11.5%) | ||
N1-3 | 46 (74.2%) | 29 (74.4%) | 17 (70.8%) | 23 (88.5%) | ||
Clinical TNM stage | 0.122 | 0.467 | ||||
I-II | 10 (16.1%) | 2 (5.1%) | 3 (12.5%) | 6 (23.1%) | ||
III-IV | 52 (83.9%) | 37 (94.9%) | 21 (87.5%) | 20 (76.9%) | ||
Radiomics score | -1.04 (-1.61, -0.41) | 0.24 (-0.16, 0.57) | < 0.001 | -1.30 (-1.65, -0.30) | 0.45 (-0.10, 0.89) | < 0.001 |